Novo takes on gut-brain axis discovery with Kallyope, focusing on obesity and diabetes
As the pharma giant pushes to keep its pipeline relevant, Novo Nordisk has inked yet another partnership — this time, with gut-brain axis company Kallyope.
The duo hopes to discover novel peptides in the obesity and diabetes space, giving Novo the option to license exclusive global rights to develop and commercialize up to six products discovered in the collaboration. Financial details weren’t shared, but we hear Kallyope will get an upfront payment, along with license fees, R&D/sales milestones, and royalties down the line.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.